Titre :

MUC1 Drives the Progression and Chemoresistance of Clear Cell Renal Carcinomas

Auteur(s) :

Bourdon, Emma [Auteur]
Swierczewski, Thomas [Auteur]
Goujon, Marine [Auteur]
Boukrout, Nihad [Auteur]
Fellah, Sandy [Auteur]
Van Der Hauwaert, Cynthia [Auteur]
Larrue, Romain [Auteur]
Lefebvre, Bruno [Auteur]
Van Seuningen, Isabelle [Auteur]
Cauffiez, Christelle [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Pottier, Nicolas [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Perrais, Michaël [Auteur]

Titre de la revue :

Cancers

Pagination :

391

Éditeur :

MDPI

Date de publication :

2024-01-17

ISSN :

2072-6694

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

While the transmembrane glycoprotein mucin 1 (MUC1) is clustered at the apical borders of normal epithelial cells, with transformation and loss of polarity, MUC1 is found at high levels in the cytosol and is uniformly ...
Lire la suite >While the transmembrane glycoprotein mucin 1 (MUC1) is clustered at the apical borders of normal epithelial cells, with transformation and loss of polarity, MUC1 is found at high levels in the cytosol and is uniformly distributed over the entire surface of carcinoma cells, where it can promote tumor progression and adversely affects the response to therapy. Clear cell renal cell carcinoma (ccRCC), the main histotype of kidney cancer, is typically highly resistant to conventional and targeted therapies for reasons that remain largely unknown. In this context, we investigated whether MUC1 also plays a pivotal role in the cellular and molecular events driving ccRCC progression and chemoresistance. We showed, using loss- and gain-of-function approaches in ccRCC-derived cell lines, that MUC1 not only influences tumor progression but also induces a multi-drug-resistant profile reminiscent of the activation of ABC drug efflux transporters. Overall, our results suggest that targeting MUC1 may represent a novel therapeutic approach to limit ccRCC progression and improve drug sensitivity.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL

Date de dépôt :

2024-02-29T04:25:19Z